Asher Mullard

Asher Mullard's AcademicInfluence.com Rankings

Asher Mullard

Biology

#3886

World Rank

#5884

Historical Rank

Neuroscience

#385

World Rank

#403

Historical Rank

Biochemistry

#384

World Rank

#457

Historical Rank

biology Degrees

Download Badge

Biology

Asher Mullard's Degrees

PhD Biochemistry University of California, San Francisco
Bachelors Biology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Asher Mullard Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Asher Mullard's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Palmitoylation of huntingtin by HIP14is essential for its trafficking and function (2006) (323)
Huntingtin-Interacting Protein HIP14 Is a Palmitoyl Transferase Involved in Palmitoylation and Trafficking of Multiple Neuronal Proteins (2004) (322)
Protein–protein interaction inhibitors get into the groove (2012) (240)
COVID-19 vaccine development pipeline gears up (2020) (190)
FDA approves 100th monoclonal antibody product (2021) (176)
Maturing antibody–drug conjugate pipeline hits 30 (2013) (164)
Deuterated drugs draw heavier backing (2016) (153)
Targeted protein degraders crowd into the clinic (2021) (152)
New drugs cost US$2.6 billion to develop (2014) (147)
2011 FDA drug approvals (2012) (144)
2018 FDA drug approvals (2019) (139)
2012 FDA drug approvals (2013) (133)
How COVID vaccines are being divvied up around the world. (2020) (112)
Merck &Co. drops osteoporosis drug odanacatib (2016) (111)
2010 FDA drug approvals (2011) (107)
FDA approves first CAR T therapy (2017) (106)
2014 FDA drug approvals (2015) (101)
Maturing antibody–drug conjugate pipeline hits 30 (2013) (100)
Reliability of 'new drug target' claims called into question (2011) (100)
2019 FDA drug approvals (2020) (99)
2013 FDA drug approvals (2014) (97)
Sting of Alzheimer's failures offset by upcoming prevention trials (2012) (97)
First targeted protein degrader hits the clinic (2019) (96)
2016 FDA drug approvals (2017) (91)
Drug repurposing programmes get lift off (2012) (85)
Presynaptic Trafficking of Synaptotagmin I Is Regulated by Protein Palmitoylation* (2004) (83)
Parsing clinical success rates (2016) (80)
2015 FDA drug approvals (2016) (76)
Mediator scandal rocks French medical community (2011) (75)
Landmark Alzheimer’s drug approval confounds research community (2021) (75)
2010 FDA drug approvals (2011) (73)
Microbiology: The inside story (2008) (71)
2017 FDA drug approvals (2018) (71)
NCI-MATCH trial pushes cancer umbrella trial paradigm (2015) (70)
From the editors (2007) (65)
BACE inhibitor bust in Alzheimer trial (2017) (64)
FDA approves fourth CAR-T cell therapy (2021) (63)
The drug-maker's guide to the galaxy (2017) (62)
Cracking KRAS (2019) (61)
New checkpoint inhibitors ride the immunotherapy tsunami (2013) (58)
New vaccine coalition targets epidemics (2016) (57)
European Lead Factory opens for business (2013) (57)
Alzheimer amyloid hypothesis lives on (2016) (57)
Flooded by the torrent: the COVID-19 drug pipeline (2020) (54)
FDA approves landmark RNAi drug (2018) (49)
Phosphatases start shedding their stigma of undruggability (2018) (47)
DNA tags help the hunt for drugs (2016) (46)
NLRP3 inhibitors stoke anti-inflammatory ambitions (2019) (44)
The cancer vaccine resurgence (2016) (43)
FDA approves first BCMA-targeted CAR-T cell therapy (2021) (39)
Fragile X disappointments upset autism ambitions (2015) (38)
Drug developers reboot anti-NGF pain programmes (2015) (37)
What does AlphaFold mean for drug discovery? (2021) (36)
Pioneering apoptosis-targeted cancer drug poised for FDA approval (2016) (36)
2017 FDA drug approvals (2015) (35)
The phenotypic screening pendulum swings (2015) (35)
Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating (2020) (35)
Can innate immune system targets turn up the heat on 'cold' tumours? (2017) (35)
Cancer metabolism pipeline breaks new ground (2016) (35)
Stem-cell discovery platforms yield first clinical candidates (2015) (34)
Biotech R&D spend jumps by more than 15% (2016) (34)
Restoring IL-2 to its cancer immunotherapy glory (2021) (33)
FDA approves dupilumab for severe eczema (2017) (32)
Could pharma open its drug freezers? (2011) (32)
Can next-generation antibodies offset biosimilar competition? (2012) (31)
FDA approval for Biogen’s aducanumab sparks Alzheimer disease firestorm (2021) (31)
IDO takes a blow (2018) (31)
Gene therapy community grapples with toxicity issues, as pipeline matures (2021) (30)
Nine paths to PCSK9 inhibition (2017) (29)
The anticounterfeiter's technological tool kit (2010) (28)
Experimental Ebola drugs enter the limelight (2014) (28)
FDA rejects NASH drug (2020) (27)
Arvinas’s PROTACs pass first safety and PK analysis (2019) (27)
Anti-amyloid failures stack up as Alzheimer antibody flops (2019) (26)
FDA approves first deuterated drug (2017) (26)
Gene-editing pipeline takes off (2020) (25)
BACE failures lower AD expectations, again (2018) (25)
Controversial Alzheimer’s drug approval could affect other diseases (2021) (25)
Pioneering apoptosis-targeted cancer drug poised for FDA approval (2016) (24)
Learning from exceptional drug responders (2014) (24)
Cholesterol-lowering blockbuster candidates speed into Phase III trials (2012) (23)
Biomolecular condensates pique drug discovery curiosity (2019) (23)
2021 FDA approvals (2022) (23)
Microglia-targeted candidates push the Alzheimer drug envelope (2018) (23)
Re-assessing the rule of 5, two decades on (2018) (22)
Drug withdrawal sends critical care specialists back to basics (2011) (22)
Addressing cancer’s grand challenges (2020) (22)
Jim O'Neill (2016) (22)
EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal (2014) (21)
FDA approves Eli Lilly's baricitinib (2018) (21)
BTK inhibitors get a boost (2017) (21)
FDA approves second BCMA-targeted CAR-T cell therapy (2022) (20)
Bispecific antibody pipeline moves beyond oncology (2017) (20)
GSK's darapladib failures dim hopes for anti-inflammatory heart drugs (2014) (20)
Second anticancer CAR T therapy receives FDA approval (2017) (20)
Small molecules against RNA targets attract big backers (2017) (19)
FDA approves first immunotherapy combo (2015) (18)
A probe for every protein (2019) (17)
FDA approves first bispecific (2014) (17)
Anti-ageing pipeline starts to mature (2018) (17)
Oncologists tap the microbiome in bid to improve immunotherapy outcomes (2018) (17)
Microbiology: Tinker, bacteria, eukaryote, spy (2009) (17)
Patient-focused drug development programme takes first steps (2013) (17)
Antibody–oligonucleotide conjugates enter the clinic (2021) (16)
Machine learning brings cell imaging promises into focus (2019) (16)
Chinese biopharma starts feeding the global pipeline (2017) (15)
p53 programmes plough on (2020) (15)
Pharma pumps up anti-tau Alzheimer pipeline despite first Phase III failure (2016) (15)
Partnering between pharma peers on the rise (2011) (14)
Gene therapies advance towards finish line (2011) (14)
Targeted degraders clear first safety hurdles (2020) (14)
Pioneering antisense drug heads into pivotal trials for Huntington disease (2019) (14)
Bispecific antibody pipeline moves beyond oncology (2017) (14)
On the origin of transformative drugs (2018) (14)
The Roadmap Epigenomics Project opens new drug development avenues (2015) (14)
FDA approves landmark tissue-agnostic cancer drug (2018) (14)
FDA approves first-in-class cancer metabolism drug (2017) (14)
First approval of a complement C3 inhibitor opens up autoimmune and inflammatory opportunities (2021) (13)
Hearing shines spotlight on biosimilar controversies (2010) (13)
Top product sales forecasts for 2018 (2018) (13)
mRNA vaccines get another booster (2018) (13)
EMA greenlights second gene therapy (2016) (13)
FDA approves antitoxin antibody (2016) (13)
How much do phase III trials cost? (2018) (13)
Stemming the tide of drug resistance in cancer (2020) (13)
Synthetic lethality screens point the way to new cancer drug targets (2017) (13)
Synthetic lethality screens point the way to new cancer drug targets (2017) (13)
Momentum builds around new antibiotic business models (2014) (12)
RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape (2021) (12)
FDA approves ADC Therapeutics’ loncastuximab tesirine, ushering in a new cytotoxic payload (2021) (12)
FDA approves first-in-class SYK inhibitor (2018) (12)
2011 in reflection (2012) (12)
Long COVID’s long R&D agenda (2021) (12)
Next-generation proteasome blockers promise safer cancer therapy (2012) (12)
FDA approves second GPCR-targeted antibody (2018) (11)
Achaogen bankruptcy highlights antibacterial development woes (2019) (11)
Cancer market hits $100 billion (2015) (11)
Cancer reproducibility project yields first results (2017) (11)
FDA approves AstraZeneca’s anifrolumab for lupus (2021) (11)
Gene silencing: Shhh! RNAi-dependent and -independent pathways at work (2007) (11)
FDA approves first-in-class osteoporosis drug (2019) (11)
FDA approves first new flu drug in 20 years (2018) (11)
PRIME time at the EMA (2017) (11)
FDA approves Novartis's CDK4/6 inhibitor (2017) (11)
Alnylam dealt blow (2009) (10)
Microfluidics platform lowers barrier to drug combination screening (2018) (10)
Pfizer exits neuroscience (2018) (10)
Alzheimer prevention failure rattles field, anew (2019) (10)
Multicompany trials adapt to disciplines beyond cancer (2014) (10)
COVID-19 vaccines buoy hope (2020) (10)
Anti-IL-6Rs falter in COVID-19 (2020) (10)
Malaria medicine box expands (2018) (10)
DNA-encoded drug libraries come of age (2016) (10)
Oral GLP1 analogue rounds Phase II corner (2015) (10)
Alzheimer prevention hopes continue to dim (2020) (10)
Novartis secures first CRISPR pharma collaborations (2015) (10)
Unleashing the Mini-Sentinel (2012) (10)
FDA approves splice-modulating drug (2017) (10)
Use of personalized cancer drugs runs ahead of the science (2015) (9)
FDA rejects first cognitive claim for antidepressant (2016) (9)
RNAi hits another rut (2016) (9)
23andMe sets sights on UK/Canada, signs up Genentech (2015) (9)
Bracing for the biosimilar wave (2017) (9)
ALS antisense drug falters in phase III (2021) (9)
IRAK4 degrader to take on innate immunity (2020) (9)
EU implicated in controversial counterfeiting bill (2010) (9)
More Alzheimer’s drugs head for FDA review: what scientists are watching (2021) (9)
Painkilling anti-NGF antibodies stage phase III comeback (2018) (9)
FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication (2021) (9)
Symptomatic AD treatment fails in first phase III (2016) (9)
Immunotherapy interest drives IDO deals (2015) (9)
FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on (2018) (9)
Calls grow to tap the gold mine of human genetic knockouts (2017) (9)
PCSK9 inhibitors are go (2015) (9)
First antibody against COVID-19 spike protein enters phase I (2020) (9)
Cancer stem cell candidate Rova-T discontinued (2019) (9)
Success of immunomodulators in MS shifts discovery focus to neuroprotection (2011) (9)
Gene therapy boom continues (2019) (8)
EMA greenlights Novartis' first-in-class IL-17 inhibitor (2014) (8)
FDA approves first all-oral sleeping sickness drug (2021) (8)
EMA opens its data vaults (2016) (8)
Amgen overcomes historically undruggable target, with FDA nod for first KRAS inhibitor (2021) (8)
Coordinating the COVID-19 pipeline (2020) (8)
FDA approves antibody cocktail for Ebola virus (2020) (8)
Accelerated approval dust begins to settle (2011) (8)
DNA repair: Making the cut (2006) (8)
PARP inhibitor pick-me-up (2019) (8)
FDA approvals for the first 6 months of 2016 (2016) (7)
European regulators approve first PARP inhibitor (2014) (7)
New plaque psoriasis approval carries suicide warning (2017) (7)
Phase III setback for lead angiopoietin inhibitor (2014) (7)
New cancer vaccines show clinical promise (2017) (7)
Molecular imaging as a de-risking tool: coming into focus? (2013) (7)
US drug spending hits $425 billion (2016) (7)
FDA approves an inhibitor of a novel ‘epigenetic writer’ (2020) (7)
FDA approves first peanut allergy drug (2020) (7)
PARP inhibitors plough on (2017) (7)
Anti-tau antibody failures stack up (2021) (7)
Reining in the supersized Phase I cancer trial (2016) (7)
Ebola outbreak prompts experimental drug rollout (2018) (7)
$215 million precision-medicine initiative takes shape (2015) (7)
2013 in reflection (2013) (7)
Tackling antimicrobial drug resistance (2016) (7)
Crowdfunding clinical trials (2015) (7)
Trispecific antibodies take to the clinic (2020) (7)
Parkinson disease repurposing promise (2017) (7)
EMA rewrites Phase I guidelines in aftermath of FAAH tragedy (2016) (7)
Industry R&D returns slip (2015) (6)
Industry advances landmark CRISPR candidate into the clinic (2018) (6)
The art of losing (2015) (6)
N-of-1 drugs push biopharma frontiers (2020) (6)
Merck readies oral, macrocyclic PCSK9 inhibitor for phase II test (2021) (6)
R&D returns continue to fall (2016) (6)
Off-label targeted cancer drugs fail in first randomized trial (2015) (6)
Finding fault with Bial's fatal FAAH inhibitor (2017) (6)
Pfizer expands hunt for immuno-oncology biomarkers (2016) (6)
Can you trust your cancer cell lines? (2018) (6)
Once-yearly device takes on daily and weekly diabetes drugs (2014) (6)
First in vivo gene-editing drugs enter the clinic (2017) (6)
FDA approves first digital pill (2017) (6)
FDA rejects first DARPin (2020) (6)
FDA approves two IBS drugs (2015) (6)
Immune evasion: Overcoming defensins (2008) (6)
Drug makers and NIH team up to find and validate targets (2014) (6)
First in vivo CRISPR candidate enters the clinic (2019) (6)
FDA approves first marijuana-derived product (2018) (6)
Fragment-based screening sees the light (2020) (6)
Hints of hope with remdesivir (2020) (6)
Synthetic lethality screens point the way to new cancer drug targets (2017) (6)
PCSK9-lowering RNAi contender clears first phase III trial (2019) (6)
FDA approves first new ALS drug in over 20 years (2017) (5)
FDA approves ultra-orphan drug on a 4-patient trial (2015) (5)
CETP set-back, again (2015) (5)
Priority review voucher pitfalls (2015) (5)
2016 EMA drug approval recommendations (2017) (5)
LAG3 pushes immuno-oncology’s leading edge (2022) (5)
FDA approves first EGFR exon 20 targeted kinase inhibitor (2021) (5)
New hope for anti-obesity drugs (2021) (5)
FDA approves anticoagulant antidote (2015) (5)
A snapshot of lead-generation strategies (2018) (5)
FDA approves first BCMA-targeted therapeutic (2020) (5)
Green light for Janssen's IL-6 blocker (2014) (5)
Roche’s anti-TIGIT drug suffers a phase III cancer setback (2022) (5)
Fragile X drug development flounders (2016) (5)
Preclinical antibiotic pipeline gets a pick-me-up (2017) (5)
Do you want chips with that? (2015) (5)
Straight talk with...Phil Willis (2011) (5)
FDA approves first drug for primary progressive multiple sclerosis (2017) (5)
Pfizer’s COVID-19 vaccine secures first full FDA approval (2021) (5)
Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis (2016) (5)
Making way for maternal immunization (2015) (5)
FDA approves first GPCR biased agonist (2020) (5)
Finding the way with LIPID MAPS (2008) (5)
COVID-19 platform trial delivers (2020) (5)
EMA recommended 35 new drugs in 2017 (2018) (5)
Oncology trials gear up for high-throughput sequencing (2012) (5)
FDA notches up third tissue-agnostic cancer approval (2019) (5)
What’s next for the synthetic lethality drug discovery engine? (2022) (4)
Regulators approve the first cancer-killing virus (2015) (4)
Affordable HIV and sickle cell disease gene therapies (2019) (4)
FDA approves RNA-targeting small molecule (2020) (4)
BACE race gains steam (2016) (4)
COVID-19 vaccines start moving into advanced trials (2020) (4)
COVID-19 brings drug development to a halt (2020) (4)
Cancer charity sees success re-prioritizing industry's shelved compounds (2014) (4)
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform (2022) (4)
FDA approvals for the first 6 months of 2015 (2015) (4)
FDA approves first PSMA-targeted radiopharmaceutical (2022) (4)
First de novo deuterated drug poised for approval (2022) (4)
Pharmaceutical firms commit US$1 billion to antibiotic development (2020) (4)
Single-cell profiling sheds new light (2011) (4)
Reining in the supersized Phase I cancer trial (2016) (4)
Daphne Koller (2019) (4)
mRNA-based drug approaches Phase I milestone (2016) (4)
Climbing cancer’s MYC mountain (2022) (4)
Robust biotech sector increases R&D spend (2015) (4)
Sanofi's dengue vaccine rounds final corner (2014) (4)
HOTAIR rises: new role for non-coding RNAs (2007) (4)
Dual fronts poised to transform melanoma therapy (2011) (4)
Second chance for dronedarone after recent setback? (2012) (4)
Amylyx’s ALS therapy secures FDA approval, as regulatory flexibility trumps underwhelming data (2022) (4)
Regulators and industry tackle dose-finding issues (2015) (4)
CETP inhibitors stumble on (2017) (4)
Underground drug networks in the early days of AIDS (2014) (4)
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval (2022) (4)
FDA approves decades-old maribavir for CMV infection (2021) (4)
FDA approves fifth RNAi drug — Alnylam’s next-gen hATTR treatment (2022) (4)
The long Avandia endgame (2011) (4)
Sarepta’s DMD gene therapy falls flat (2021) (4)
Cancer drug developers counteract kinase gatekeeper mutations (2015) (4)
Economists propose a US$30 billion boost to biomedical R&D (2012) (4)
Sepsis researchers set sights on immunotherapeutic strategies (2018) (4)
FDA approves first drug for Parkinson disease psychosis (2016) (4)
COVID-19 vaccine guidelines (2020) (4)
COVID umbrella trials multiply (2020) (4)
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics (2022) (4)
FDA authorizes first single-shot COVID-19 vaccine (2021) (4)
Cardiovascular pipeline decline quantified (2016) (3)
FDA approves first-in-class TSLP-targeted antibody for severe asthma (2022) (3)
FDA approves first-in-class KRAS inhibitor. (2021) (3)
Immuno-oncology target TIGIT attracts a new contender (2021) (3)
The quest to prevent MS — and understand other post-viral diseases (2022) (3)
Learning from the 2012–2013 class of breakthrough therapies (2013) (3)
2022 FDA approvals (2023) (3)
Diabetes drug shows promise in Parkinson disease (2017) (3)
WHO heads back to the drug development drawing board (2010) (3)
Mechanisms of disease: Inhibiting γ-secretase activity (2007) (3)
Outcome results renew debate about diabetes drug development. (2013) (3)
Do you want chips with that? (2015) (3)
Low-cost non-profit drug repurposing (2018) (3)
FDA rejects first-in-class osteoporosis drug (2017) (3)
2011 in reflection (2012) (3)
Boehringer Ingelheim experiments with open-access chemical probes (2017) (3)
KRAS’s undruggability cracks? (2019) (3)
Bank tests drug development waters (2014) (3)
Paring down the placebo response (2016) (3)
Cell signalling: Asymmetry in action (2006) (3)
Faecal matter transplants boost immuno-oncology efficacy (2021) (3)
Fitness partners beat the heat (2007) (3)
RNAi agents score an approval and drive an acquisition (2019) (3)
Bacteria could help control dengue fever (2009) (3)
Tezepelumab prepares to enter the asthma antibody fray (2021) (3)
Supersized virtual screening offers potent leads (2019) (3)
Built-to-buy start-ups begin to bloom (2014) (3)
Leading microbiome-based therapeutic falters in Phase II trial (2016) (3)
$1.3 billion per drug? (2020) (3)
The FDA approves a first farnesyltransferase inhibitor (2020) (3)
Pharmaceutical market growth set to slow? (2019) (2)
Access to medicines report cards (2016) (2)
COVID-19 vaccine success enables a bolder vision for mRNA cancer vaccines, says BioNTech CEO (2021) (2)
COVID antibody drugs have saved lives — so why aren’t they more popular? (2022) (2)
UK to train 2,000 new PhDs (2008) (2)
Anti-inflammatory cardiovascular therapies take another hit (2018) (2)
WHO report on drug development marred by big pharma leak (2010) (2)
FDA approvals for the first 6 months of 2017 (2017) (2)
Epigenomic colon cancer kit (2009) (2)
Amarin agreement opens off-label promotion door (2016) (2)
European regulators launch 'breakthrough' equivalent programme (2016) (2)
Smallest biopharma firms are pushing more of the pipeline (2019) (2)
REVAMPing antibiotic incentives (2018) (2)
DNA damage response drugs for cancer yield continued synthetic lethality learnings (2022) (2)
FDA approves female sexual dysfunction drug (2015) (2)
Moncef Slaoui (2015) (2)
Proliferation without differentiation (2008) (2)
The BCMA bonanza (2019) (2)
Post-translational modification: Picking apart polyubiquitin chains (2008) (2)
Blood–brain barrier-traversing biologic secures regulatory approval, in Japan (2021) (2)
NIAID amps up vaccine adjuvant work (2014) (2)
Second CTLA4-targeted checkpoint inhibitor secures FDA approval (2022) (2)
EMA recommended approval for 40 new drugs in 2014 (2015) (2)
Biotech gender gap (2017) (2)
Genetic biomarker trumps tissue type in landmark oncology approval (2017) (2)
UK outlines its antibiotic pull incentive plan (2020) (2)
Two competing RSV vaccines round final phase III corner (2022) (2)
Failure of Seres’s phase II ulcerative colitis programme renews microbiome concerns (2021) (2)
Biogen Idec enters hemophilia B market (2014) (2)
Make or break for first splice-modulating agents (2013) (2)
First-in-class tissue factor-targeted antibody–drug conjugate secures FDA approval (2021) (2)
An audience with Jay Bradner (2017) (2)
FDA approves first targeted drug for acute myelogenous leukaemia (2017) (2)
FDA approves first haemophilia B gene therapy (2022) (2)
EMA recommended 39 new drug approvals last year (2016) (2)
The deadly burden of drug-resistant bacteria (2022) (2)
Cancer drug approvals and setbacks in 2021 (2021) (2)
EMA approves first ever malaria vaccine (2015) (2)
NIH tackles clinical trial shortcomings (2016) (2)
Novartis’s canakinumab stumbles in cancer, again (2021) (2)
Accelerated approvals under the microscope (2021) (2)
Straight talk with...Aline Plançon (2010) (2)
Mediator scandal engulfs French compensation body (2013) (2)
PDUFA V goes back to basics (2012) (2)
FDA unveils searchable adverse events system (2017) (2)
Vaccine failure explained (2008) (2)
FDA outlines steps for individualized drug development (2021) (2)
Tatsuya Kondo (2014) (1)
Parkinson pipeline pare back (2021) (1)
FDA approves oral version of diabetes biologic (2019) (1)
Innovative antidepressants arrive (2019) (1)
Should the FDA disclose complete response letters? (2015) (1)
FDA plans Office of Drug Evaluation Science (2019) (1)
Flagella and cilia come of age: Cilia and flagella formation and function (2010) (1)
Development: Notch mediates the sprouting of tip cells (2007) (1)
Ebola vaccine success (2017) (1)
MDMA scores PTSD success in a landmark phase III trial (2021) (1)
Cancer mouse models carry genomic inconsistencies (2017) (1)
New naming scheme for antibodies drops the -mab stem (2022) (1)
Development: Notch mediates the sprouting of tip cells (2007) (1)
Therapeutic developments: Masters of medicine (2017) (1)
Monoclonal antibodies show promise in phase I malaria trial (2021) (1)
CRISPR technologies are going to need a bigger toolbox (2021) (1)
$215 million cancer immunotherapy biomarker consortium debuts (2017) (1)
Induced protein proximity drug discovery, from 30,000 feet (2022) (1)
FDA advisory committee votes for approval of first microbiome-based drug, despite data problems (2022) (1)
Pull incentives for antibiotics get push from the UK (2022) (1)
Neglected disease R&D funding hits new high (2019) (1)
Anti-CD3 antibody charts out a type 1 diabetes comeback (2019) (1)
Nigel Blackburn (2017) (1)
Panel meeting prompts excitement for antiobesity drug (2012) (1)
Menelas Pangalos (2013) (1)
What does Pfizer's merger mean for drug development? (2016) (1)
FDA approves anti-CD3 antibody to delay type 1 diabetes onset (2022) (1)
FDA approves first cardiac myosin inhibitor (2022) (1)
Bracing for the biosimilar wave (2017) (1)
Breakthrough programme turns two (2014) (1)
FDA approves first-in-class HIV capsid inhibitor (2023) (1)
Charting the decline of US biomedical research funding (2015) (1)
Infectious Disease: Finding the keys to the placental barrier (2008) (1)
Straight talk with...Ellen 't Hoen (2010) (1)
NCI starts 'exceptional responder' hunt (2014) (1)
Priority review vouchers miss the policy mark (2020) (1)
FDA approves SMA gene therapy (2019) (1)
Ebola vaccine yields first hopes of clinical efficacy (2015) (1)
FDA approves first drug under new antibacterial and antifungal drug programme (2018) (1)
CAR–T cell companies cash in (2015) (1)
UK DNA database needs overhaul (2008) (1)
From the editors (2007) (1)
Hal Barron (2019) (1)
Molecular motors: Power in numbers (2008) (1)
Clinuvel's tanning agent nears approval for porphyria (2015) (1)
Lipids: Orientating with PtdIns(3,4,5)P3 (2008) (1)
Reflections on 10 years of the FDA’s breakthrough therapy designation (2022) (1)
HIV vaccine suffers setback (2020) (1)
Microscopy: Eukaryotic cell, now showing in 3D (2007) (1)
Husseini Manji (2015) (1)
Industry head-to-head trials favour sponsor (2015) (1)
Understanding how microbiome bugs metabolize drugs (2019) (1)
Biogen files ALS drug for FDA review, putting neuroscience-accelerated approvals back in the hot seat (2022) (1)
Cancer model consortium debuts (2016) (1)
Pliant’s integrin inhibitor boosted by phase II IPF data (2022) (1)
Novartis' lung cancer ALK inhibitor approved (2014) (1)
Cures Act shakes up the FDA and NIH (2016) (1)
First biosimilar antibody nears US approval (2016) (1)
John P. A. Ioannidis (2014) (1)
Skin cancer on the rise (2009) (1)
Malaria: Sticking around (2007) (1)
Mechanisms of disease: Kinases out of control — brake line cut! (2007) (1)
Cheating bacteria could treat infections (2009) (1)
Steve Blank (2014) (1)
Silent mutations turn up the volume (2007) (1)
Large pharmas set up screening library data-sharing experiment (2019) (1)
Roche snaps up another NLRP3 contender (2020) (1)
Sickle cell disease celebration (2019) (1)
What is the link between autism and testosterone (2009) (1)
Merck & Co. pays US$1.35 billion for LSD1 inhibitors (2022) (1)
The KRAS crowd targets its next cancer mutations (2023) (1)
Parkinson disease setback (2020) (1)
EMA provides first glimpse of PRIME candidates (2016) (1)
The genes that drive speciation (2008) (1)
CRISPR pioneers win Nobel prize (2020) (1)
Reverse transcription: Do the flip (2008) (1)
Consumer gene tests poised for regulatory green light (2012) (1)
Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis (2016) (1)
Biotech R&D spending continues to rise (2017) (1)
FDA approves first new sickle cell drug in 20 years (2017) (1)
The Nobel Prize-winning path from oxygen sensing research to new drugs (2021) (1)
Anticoagulant loses its lustre (2012) (1)
Bob More (2014) (1)
NIH launches open science Alzheimer initiative (2019) (1)
Malaria: Picking Plasmodium falciparum apart (2008) (1)
DPP4 inhibitors dodge cardiovascular bullet (2015) (1)
Will psychedelics be ‘a revolution in psychiatry’? (2021) (1)
Chugai reports Actemra deaths (2009) (1)
RNAi drugs at “a remarkable period of a renaissance” (2021) (1)
Better screening and disease models needed (2016) (1)
Symbiosis: Show me the sugar (2008) (1)
What new GSK patent policy means for the developing world (2016) (1)
BCMA-targeted bispecific gets first green light, in the EU (2022) (1)
Tiny springboards detect viruses in fluids (2009) (0)
What should go into a booster shot for COVID-19? (2022) (0)
Calculating cancer drug value (2015) (0)
Novo Nordisk and GlaxoSmithKline buy into RNAi (2021) (0)
Cytoskeleton: Nibbling away at actin organization (2006) (0)
Austerity threatens pharma beyond borders of cost cutters (2010) (0)
Clinical trial transparency, take two (2014) (0)
Mechanisms of disease: Prions hijack the nanotube (2009) (0)
What makes a cancer stem cell (2009) (0)
Industry tightens its purse strings (2009) (0)
Pfizer buys Trillium and its CD47 candidates for US$2.3 billion (2021) (0)
Cell migration: The flight of the haemocyte (2006) (0)
Keith Blundy (2014) (0)
Next-generation gene-editing platforms drive CRISPR deals (2022) (0)
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion (2022) (0)
Nanog's new trick (2008) (0)
Kathy High (2021) (0)
NCATS launches 'periodic table' for medicinal product ingredients (2016) (0)
FDA approves first anti-IL-36 receptor antibody for rare skin disease (2022) (0)
AstraZeneca to acquire Alexion (2020) (0)
Metagenomics: Phages apart (2008) (0)
In this issue (2007) (0)
WAH-1 and SCRM-1 make lipids flip (2007) (0)
Chi-Med scores key approval for 'discovered in China' cancer drug (2018) (0)
Vertex’s NaV1.8 inhibitor passes phase II pain point (2022) (0)
PARPs pick-up (2016) (0)
Immuno-oncology upset in bladder cancer (2017) (0)
Mike Varney (2015) (0)
Stanley Crooke (2019) (0)
Development: Purine to my eyes (2007) (0)
Cell signalling condensed (2006) (0)
Eric Karran (2015) (0)
Dan Tagle (2013) (0)
Can a platform of platform companies open up more opportunities? (2021) (0)
Willing subjects live longer but blur clinical trial results (2009) (0)
In this issue (2007) (0)
Archaea: Kings of the sea floor? (2008) (0)
Entasis antibiotic shows phase III promise (2021) (0)
AstraZeneca to buy rare disease specialist Alexion for $39 billion (2020) (0)
DNA replication: Follow the path (2008) (0)
Vertex combo scores a broader cystic fibrosis approval (2015) (0)
Antibiotics funding splurge gets mixed reception (2016) (0)
Leena Gandhi (2020) (0)
Novel excipient review programme aims to bolster formulation innovation (2021) (0)
Gene therapy pushes the US $1 million price barrier (2014) (0)
Engineered IL-2 cytokine takes pivotal immuno-oncology blow (2022) (0)
FDA approves drug from transgenic chicken (2015) (0)
FDA approves bispecific antibody for two eye diseases (2022) (0)
Escorting siRNA (2008) (0)
Jessica Mega (2019) (0)
Patent income tax slashed (2010) (0)
Broadly neutralizing antibody misses in HIV prophylaxis trial (2021) (0)
Roche hits multiple sclerosis landmarks (2015) (0)
C&EN talks with NCATS’s Christopher Austin (2021) (0)
Cell/gene potency guides (2008) (0)
Enbrel patent feud (2008) (0)
Cell division: Inn a pinch (2008) (0)
BRAIN gain (2014) (0)
Development: MicroRNA knocks some sense into senseless (2006) (0)
Celgene samples from science smorgasbord (2015) (0)
ADCs inspire large pharma investments (2020) (0)
Microbial ecology: Baby boom (2007) (0)
Pierre Meulien (2015) (0)
Aviv Regev (2021) (0)
FDA approves first anti-C1s antibody, targeting innate immunity for rare anaemia (2022) (0)
FDA releases tissue-agnostic cancer drug draft guidance (2022) (0)
Sandra Horning (2020) (0)
Of cows and men (2006) (0)
Emer Cooke (2020) (0)
Recipes for results (2006) (0)
R&D budgets boom, but success rates falter (2022) (0)
From the editors (2007) (0)
Novartis grows its gene therapy ambitions (2018) (0)
Chris Austin (2013) (0)
Human cell assays for new medicines now open access (2015) (0)
US FDA outlines how to adapt COVID-19 vaccines, drugs and diagnostics to virus variants (2021) (0)
Phase II antisense sets Crohn disease precedents (2015) (0)
Melissa Paoloni (2016) (0)
Systems biology with a view (2006) (0)
PDUFA V goes back to basics (2012) (0)
Environmental Microbiology: Arsenic in action (2008) (0)
Myosin inhibitor flexes, myosin activator flops (2020) (0)
From the editors (2007) (0)
Peanut allergy potential (2018) (0)
From the editors (2007) (0)
Alzheimer antibody rush begins, as efficacy concerns remain (2021) (0)
New funding needed for late-stage vaccine work? (2019) (0)
Large drug firms narrow their therapeutic interests (2014) (0)
BMS sells diabetes business (2014) (0)
Reshma Kewalramani (2019) (0)
AbbVie pays $21 billion for Pharmacyclics' BTK inhibitor (2015) (0)
Fat busting: the search for a safe and effective diet drug (2012) (0)
David Urdal (2011) (0)
From the editors (2007) (0)
From the editors (2007) (0)
Open-access fermenter (2010) (0)
Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors? (2022) (0)
A new path to targeted protein degradation? (2022) (0)
Electroceuticals jolt into the clinic, sparking autoimmune opportunities (2022) (0)
Zafgen charts unique path to obesity approval (2015) (0)
From the editors (2007) (0)
Inadvertent parthenogenesis (2007) (0)
TransCelerate makes progress (2017) (0)
Protein degradation: Examining E1 (2008) (0)
Vas Narasimhan (2015) (0)
Ipsen buys Epizyme for US$247 million (2022) (0)
Stéphane Bancel (2015) (0)
Roche buys $1 billion majority stake in Foundation (2015) (0)
HIV: Do the flip (2008) (0)
Cellular microbiology: Examining the Fic domain (2009) (0)
Merck & Co. to buy Acceleron and its TGF-β ligand traps (2021) (0)
A map of mRNA localization (2007) (0)
FDA releases proposed terms of PDUFA VII agreement (2021) (0)
Sage gets an antidepressant lift (2017) (0)
RSV antibody showcases passive immunotherapy progress (2020) (0)
In this issue (2007) (0)
John Jenkins (2017) (0)
First clinical test of an in vivo CRISPR candidate shows deep protein knockout potential (2021) (0)
Longer-lasting HIV drugs (2019) (0)
In this issue (2011) (0)
What’s next for an immuno-oncology powerhouse? (2021) (0)
Cell cycle: Achieving entry (2008) (0)
John Tsai (2019) (0)
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline (2022) (0)
Cancer drug developers counteract kinase gatekeeper mutations (2015) (0)
Plant stem cells, not so different (2009) (0)
Cell division: Sensor of tension gets honourable mention (2007) (0)
Industry gets mixed transparency grades (2015) (0)
GPRC5D-targeted bispecific bolsters T-cell-engager pipeline (2023) (0)
In This Issue (2013) (0)
Francis Cuss (2015) (0)
Prions: Prions hijack the nanotube (2009) (0)
RAC to finally relax gene therapy oversight (2014) (0)
Parsing exceptional responders (2020) (0)
Mechanisms of disease: A spate of RAB8 (2007) (0)
FDA tackles gene–drug interactions (2020) (0)
FDA approves first drug for common form of dwarfism (2021) (0)
Amgen cues up pivotal KRAS data (2020) (0)
FDA's rejection of alemtuzumab divides neurologists (2014) (0)
15 states sue Amgen (2010) (0)
Industry gains on moneyback schemes (2010) (0)
Viral evolution: As the crow dies (2007) (0)
Ted W. Love (2020) (0)
PARP inhibitors' revival (2014) (0)
Where did the membrane go? (2007) (0)
BMS buys Turning Point Therapeutics and its kinase inhibitors for $4.1 billion (2022) (0)
From the editors (2007) (0)
Disease interception at scale: how a five-million-person study plans to transform healthcare (2022) (0)
Mechanisms of disease: Getting back to β-cell basics (2008) (0)
Pharma fesses up to freebies (2010) (0)
Randomness versus order: Whole genome shotgun (2007) (0)
Web watch (2008) (0)
Gregory Lip (2012) (0)
Malaria vaccine shows phase II promise, advances into phase III (2021) (0)
Neurons on border patrol (2008) (0)
Bacterial genetics: Resistance in 18 steps (2007) (0)
'Mini-hibernation' essential for winter survival (2009) (0)
Neurodegenerative diseases: Perils of ageing (2006) (0)
Humans and sponges may share a slimy ancestor (2009) (0)
Wayne Koff (2014) (0)
David Liu (2019) (0)
Pfizer’s small-molecule antiviral misses on COVID prevention (2022) (0)
Immuno-oncology drugs jostle for first-line setting (2016) (0)
Henry Chesbrough (2013) (0)
Development: Sharing the signalling components (2007) (0)
Protein evolution: Tracing the evolution of structure and function (2007) (0)
From the editors (2007) (0)
GSK scores first Phase III shingles trial success (2015) (0)
Development: A force to be reckoned with (2008) (0)
In this issue (2010) (0)
Cloned monkeys yield stem cells (2008) (0)
The UK Biobank at 20 (2022) (0)
Antibody clamps pry open small-molecule drug discovery opportunities (2022) (0)
Tillman Gerngross (2020) (0)
Meiosis: The telomere bouquet takes control (2007) (0)
In this issue (2010) (0)
RNAi deal flow heats up (2018) (0)
John Reed (2014) (0)
Sponsors rarely disclose Refuse-to-File letters, finds study of regulatory transparency gap (2021) (0)
Post-translational modification: Examining the Fic domain (2009) (0)
Busy panels recommend Pfizer's tofacitinib, Arena's lorcaserin and more (2012) (0)
Mechanisms of disease: Perils of ageing (2006) (0)
HIV helpers can be hijacked (2008) (0)
PCSK9 pipeline (2016) (0)
Audio long-read: The quest to prevent MS - and understand other post-viral diseases. (2022) (0)
Reprogrammed skin cells provide testing ground for new drugs (2008) (0)
Antibiotics take a radical approach (2007) (0)
FDA approves second anti-amyloid antibody for Alzheimer disease (2023) (0)
From the editors (2007) (0)
Should everyone have an HIV test (2008) (0)
Proof-of-principle Intellia trial shows in vivo CRISPR activity (2022) (0)
Roche, Biogen and AbbVie stake new gene therapy claims (2019) (0)
Randy Mills (2015) (0)
On the hunt for monomeric degraders (2021) (0)
Circadian rhythms: Setting the clock (2006) (0)
Andy Plump (2019) (0)
DNA replication: Follow the path (2008) (0)
Doug Williams (2014) (0)
Stem cells: Stemming the tide (2016) (0)
From pandemic preparedness to public–private partnerships (2022) (0)
Straight talk with ... Peter Piot (2010) (0)
Provinces lead the way towards pharmacare in Canada (2017) (0)
A new pluripotency factor can stand in for two others (2009) (0)
'Skin deep' goes to a new depth (2008) (0)
Drug pricing under the spotlight (2019) (0)
Cashing in with off-the-shelf CAR Ts (2018) (0)
Genetics of cancer relapse revealed (2008) (0)
FDA relaxes cardiovascular trial requirements for diabetes drugs (2020) (0)

This paper list is powered by the following services:

Asher Mullard's Academic­Influence.com Rankings

Asher Mullard's Degrees

Similar Degrees You Can Earn

Why Is Asher Mullard Influential?

Asher Mullard's Published Works

Published Works

Asher Mullard's AcademicInfluence.com Rankings